Table 2:
Laboratory findings of the participants at baseline and at the end of the study after treatment with high dose and low dose of folic acid (Group1: treat with 5 mg and Group2 with 0.5 mg folic acid)
| Variable | Group1(n=23) | Group2(n=22) | P value 5 |
|---|---|---|---|
| Serum OPG1(pg/ml) | |||
| Baseline | 340(120–1200) | 375(160–1310) | 0.488 |
| 36thweek | 710(120–1500) | 470(130–1400) | |
| (P=0.008)4 | (P=0.592)4 | ||
| Serum sRANKL2 (pg/ml) | |||
| Baseline | 91.6(33.40–198.60) | 86.10(39.70–198.60) | 0.302 |
| 36thweek | 40(20.10–100.20) | 76.50(43.70–188.5) | |
| (P<0.001)4 | (P=0.426)4 | ||
| Serum TNFα3 (pg/ml) | |||
| Baseline | 5.30(4.10–10.20) | 5.85(4.20–8.90) | 0.251 |
| 36thweek | 4.80(2.50.–9.00) | 6.5(5.00–8.80) | |
| (P=0.005)4 | (P=0.135)4 | ||
| Serum sRANKL/OPG | |||
| Baseline | 0.27 (0.28–0.17) | 0.23(0.25–0.15) | 0.555 |
| 36thweek | 0.06(0.17–0.05) | 0.16(0.34–0.14) | |
| (P<0.001)4 | (P=0.211)4 |
1
OPG, Osteoprotegerin;
2
sRANKL, soluble Receptor Activator of Nuclear Factor-kappa B ligand;
3
TNFα, Tumor Necrosis Factorα; Data are expressed as median (minimum–maximum).
4
Differences between before treatment and after treatment with high dose or low dose. (Values were obtained by a Wilcoxon test.) /
5
Baseline high dose group vs. low dose group. (Values were obtained by Mann–Whitney U-test)